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improves renal function at reperfusion
A Sandouka1, BJ Fuller2, BE Mann3, CJ Green1, R Foresti1 and R Motterlini1
1Vascular Biology Unit, Department of Surgical Research, Northwick Park Institute for Medical Research, Harrow, Middlesex, UK; 2Royal
Free & UCL Medical School, Royal Free Hospital, London, UK and 3Department of Chemistry, University of Sheffield, Sheffield, UK
Low concentrations of carbon monoxide (CO) can protect
tissues against ischemia–reperfusion (I–R) injury. We have
recently identified a novel class of compounds, CO-releasing
molecules (CO-RMs), which exert important pharmacological
activities by carrying and delivering CO to biological systems.
Here, we examined the possible beneficial effects of CO
liberated from CO-RMs on the damage inflicted by cold
storage and I–R in isolated perfused kidneys. Hemodynamic
and biochemical parameters as well as mitochondrial
respiration were measured in isolated perfused rabbit
kidneys that were previously flushed with CO-RMs and stored
at 41C for 24 h. Two water-soluble CO-RMs were tested: (1)
sodium boranocarbonate (CORM-A1), a boron-containing
carbonate that releases CO at a slow rate, and (2)
tricarbonylchloro(glycinato)ruthenium(II) (CORM-3), a
transition metal carbonyl that liberates CO very rapidly in
solution. Kidneys flushed with Celsior solution supplemented
with CO-RMs (50 lM) and stored at 41C for 24 h displayed
at reperfusion a significantly higher perfusion flow rate
(PFR), glomerular filtration rate, and sodium and glucose
reabsorption rates compared to control kidneys flushed with
Celsior solution alone. Addition of 1H-[1,2,4]oxadiazolo[4,
3-alpha]quinoxalin-1-one (ODQ), a guanylate cyclase
inhibitor, prevented the increase in PFR mediated by CO-RMs.
The respiratory control index from kidney mitochondria
treated with CO-RMs was also markedly increased. Notably,
renal protection was lost when kidneys were flushed with
Celsior containing an inactive compound (iCO-RM), which
had been deliberately depleted of CO. CO-RMs are effective
therapeutic agents that deliver CO during kidney cold
preservation and can be used to ameliorate vascular activity,
energy metabolism and renal function at reperfusion.
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Kidney transplantation is the treatment of choice for end-
stage renal disease.1 Most kidneys prior to transplantation are
exposed to a period of cold storage (CS), which can limit but
not completely avoid tissue injury and graft dysfunction in
transplanted patients.2 Therefore, new strategies for mitigat-
ing cold ischemic damage and novel therapies for successful
kidney transplantations are required. CS procedures are
widely used for preserving cadaveric kidneys prior to
transplant; these techniques involve intravascular flushing
of the isolated organ using a hypothermic solution followed
by storage at low temperatures for the time required to
transfer the graft to the surgery unit. In addition to the injury
imposed by CS, kidneys are subjected to further damage at
reperfusion when warm oxygenated blood (371C) is reintro-
duced into the transplanted graft. The pathophysiological
consequences of CS followed by warm reperfusion involve
cellular edema and the generation of reactive oxygen species,
which trigger acute inflammatory responses and promote
apoptosis once the graft is transplanted.3,4 Mitochondria are
a key contributor to cell survival, as mitochondrial respira-
tion and oxidative phosphorylation are essential for keeping
the adenosine 50 triphosphate demands and restoring cellular
energy after adenosine 50 triphosphate depletion caused by
ischemia.5
Several approaches have been used to counteract the
damaging mechanisms of CS-mediated injury and conse-
quently ameliorate renal function at transplantation. Perhaps
one of the most surprising and unforeseen strategies involves
the use of carbon monoxide (CO), which has recently
attracted attention as a fundamental cell signalling mediator
and cytoprotective agent against apoptosis and ischemia–
reperfusion (I–R) injury.6 Low levels of CO are produced
endogenously in mammalian tissues by heme oxygenase
(HO), the first and rate-limiting step in heme catabolism.7,8
Different types of HO enzymes have been characterized,
including constitutive (HO-2) and inducible (HO-1) iso-
forms. HO-1 is a stress protein that possesses the peculiar
feature of being finely upregulated by stimuli or pathological
events that trigger oxidative and nitrosative stress.9,10 The
induction of HO-1 and the consequent increase in endo-
genous CO production play important roles in vasorelaxa-
tion,11,12 inhibition of cell proliferation,13,14 blockade of
apoptotic pathways,15 suppression of inflammation,16
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protection against organ rejection,17 and I–R injury.18 In
essence, both the use of potent HO-1 inducers and
administration of low doses of CO gas have been employed
to evaluate and sustain a therapeutic role of CO in I–R injury
in the kidney.18–22
As a novel approach to deliver CO, our group has recently
identified a class of compounds, termed CO-releasing
molecules (CO-RMs), which are able to transport and release
CO both in vivo and in vitro in a controllable manner under
physiological conditions.23,24 Different types of CO-RMs
have been characterized and their biological activities
assessed. Two water-soluble CO-RMs have recently shown
promising results in our studies: tricarbonylchloro(glycina-
to)ruthenium(II) (CORM-3), a metal carbonyl complex that
rapidly liberates CO in physiological buffers,24,25 and sodium
boranocarbonate (CORM-A1), a newly identified generator
of CO that does not contain a transition metal and liberates
CO at a much slower rate under physiological conditions.26
The specific effect of CO liberated from CO-RMs in
modulating important physiological effects has been con-
firmed by the parallel use of specific inactive compounds
(iCO-RMs), which do not liberate CO in the cellular
environment.23,25,26 Previous data from our own laboratory
and results provided by collaborators support a critical role
for CO-RMs in vasorelaxation,23,26,27 suppression of inflam-
mation,28 protection against hypoxia–reoxygenation, and
oxidative stress as well as mitigation of I–R injury,25 allograft
rejection,25 and myocardial infarction.29,30 Thus, the hypo-
thesis that low concentrations of CO released from CO-RMs
could protect against cold ischemia-mediated injury and be
used as a novel therapeutic strategy for organ preservation
and transplantation is tantalizing. This study was designed to
assess how cold preservation of kidneys in the presence of
CO-RMs could affect renal biochemical and physiological
functions at reperfusion using an ex vivo isolated kidney
preparation.
RESULTS
Effects of CO-RMs on renal function in fresh isolated kidneys
To decide upon the effective dose range to be used in the cold
preservation protocols, the effect of 0, 10, 25 and 50 mM
CORM-A1 was examined over a 45 min perfusion time on
the isolated perfused kidney (Figure 1). Addition of 50 mM
CORM-A1 significantly increased perfusion flow rate (PFR)
compared to controls (Figure 1a). On the other hand, there
was no detectable increase in PFR with 10 and 25 mM CORM-
A1; notably, iCORM-A1 (50 mM), which does not release CO,
was also totally ineffective (Figure 1b). CORM-A1, but not
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Figure 1 | Effect of CORM-A1 on renal hemodynamics in freshly isolated kidneys. (a) Perfusion flow rate, (c) urine flow rate, and
(e) glomerular filtration rate (GFR) were measured in freshly isolated rabbit kidneys perfused for 45 min in the presence of increasing
concentrations of CORM-A1 (see Materials and Methods for details). Changes in these hemodynamic parameters were also followed over time
after the addition of 50 mM CORM-A1 (see graphs b, d, and e, respectively). iCORM-A1, which does not release CO, was used as a negative
control. Each bar or line represents the mean7s.e.m. of six independent experiments. *Po0.05 vs 0 mM CORM-A1 or control (CON).
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iCORM-A1, also significantly increased urine flow rates
(UFR) (Po0.05) in a time- and concentration-dependent
manner when compared to the control group (Figure 1c and
d). Similarly, perfusion of isolated kidneys in the presence of
CORM-A1 resulted in a marked concentration- and time-
dependent increase in glomerular filtration rate (GFR), but
no significant changes were observed with the negative
control, iCORM-A1 (Figure 1f and e). Interestingly, another
water-soluble CO carrier (CORM-3) did not cause any
change in the renal hemodynamics of freshly isolated kidneys
(data not shown).
Detection of CO release from CO-RMs in Krebs perfusion
buffer (371C) and Celsior solution (41C)
The rate and amount of CO liberated from CO-RMs were
measured in the solutions used for kidney perfusion as well as
organ preservation. We found that the rate of CO release by
CORM-A1 in Krebs solution at 371C directly correlates with
the concentrations used (Figure 2a). Specifically, the
calculated rates of CO release were 6.1670.12, 14.5070.66,
and 30.1671.33 nmol/h for 10, 25, and 50 mM CORM-A1,
respectively. Predictably, iCORM-A1 did not release any
detectable CO in the Krebs solution at 371C (Figure 2a).
Given the fact that 50 mM CO-RMs was chosen as the ideal
concentration for preserving kidneys at low temperatures, we
measured the kinetics of CO release from CORM-A1 and
CORM-3 in Celsior solution at 41C. As observed with Krebs
solution, we found that the addition of iCO-RMs to
deoxymyoglobin dissolved in Celsior solution at 41C did
not produce any detectable carbonmonoxy myoglobin over a
24 h period (data not shown). Addition of CORM-3 (50 mM)
increased carbonmonoxy myoglobin formation over time,
reaching a maximal level after 4 h; the rate of CO release in
the first 2 h was calculated as 14.071.0 nmol/h (see Figure
2b). Interestingly, and in contrast to CORM-3, the increase
in carbonmonoxy myoglobin after the addition of 50 mM
CORM-A1 to the cold Celsior solution was slower and
the calculated rate of CO release was only 1.3970.05 nmol/h
(see Figure 2b).
CS of kidneys in the presence of CO-RMs increases renal
function at reperfusion
Kidneys flushed in the presence of CORM-A1 and CORM-3
prior to 24 h CS in Celsior solution (CSþCO-RMs)
produced a significantly higher (Po0.05) PFR on the isolated
system at reperfusion (Figure 3a and b). In addition, the use
of both CO-RMs during the flushing procedure of kidneys
prior to CS significantly increased UFR (Figure 4a and b)
and GFR (Figure 5a and b) (Po0.05). Interestingly, all the
renal parameters evaluated (PFR, UFR, and GFR) were not
affected when kidneys were flushed with Celsior solution
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Figure 2 | Detection of CO released from CO-RMs at 371C and 41C.
(a) Time course of CO released from CORM-A1 (10, 25, and 50mM)
after incubation in Krebs perfusion buffer (pH¼ 7.4) at 371C. iCORM-
A1, which does not release CO, was used as a negative control.
(b) Time course of CO released from 50 mM CORM-A1 and CORM-3
after incubation in Celsior solution (pH¼ 7.4) at 41C. In both
experiments, the amount of CO released was assessed spectro-
photometrically by measuring the conversion of deoxymyoglobin to
carbonmonoxy myoglobin (MbCO). Each line represents the
mean7s.e.m. of two independent experiments. The rate of CO
release was calculated from the fitted curves as reported in the
Results section.
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Figure 3 | Effect of CO-RMs on perfusion flow rate in isolated
kidneys after cold storage. Rabbit kidneys were initially flushed
with Celsior solution alone or supplemented with (a) 50 mM CORM-A1
or (b) CORM-3 and then subjected to a 24 h cold storage (CS) (see
Materials and Methods for details). Perfusion flow rate was then
measured in isolated kidneys over 90 min after a period of initial
equilibration. iCORM-A1 and iCORM-3, which do not release CO, were
used as negative controls. Each line represents the mean7s.e.m. of
n¼ 6 for each group. *Po0.05 vs CS group.
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supplemented with the negative controls (iCO-RMs),
indicating that CO liberated from CO-RMs was directly
involved in the improved renal function at reperfusion.
CO-RMs improve mitochondrial respiration at reperfusion
after 24 h CS
As mitochondrial function contributes significantly to the
outcome of I–R injury in organ transplantation,5 we assessed
the influence of CO liberated from CO-RMs during CS on
mitochondrial oxygen consumption and viability (Figure 6).
Cold preservation (24 h) followed by 2 h reperfusion resulted
in a significant decrease in the renal mitochondria respiratory
control index (RCI) from 4 (control) to 2.5. Remarkably,
the use of CO-RMs during CS resulted in a statistically
significant (Po0.05) improvement of RCI values (RCI¼ 4.6
with CORM-A1; RCI¼ 4.5 with CORM-3).
ODQ, a guanylate cyclase inhibitor, abolishes the
vasodilatory effects of CO-RMs
Figure 7 shows the effect of 1H-[1,2,4]oxadiazolo[4,
3-alpha]quinoxalin-1-one (ODQ), an inhibitor of soluble
guanylate cyclase,27 on PFR in freshly isolated kidneys
perfused with CORM-A1 (Figure 7a) and in kidneys
subjected to CSþCORM-A1 and reperfusion (Figure 7b).
In both conditions, the effect of CORM-A1 treatment on PFR
was completely abolished by the presence of ODQ (30 mM).
PFR was not affected at reperfusion when kidneys were
flushed with Celsior containing ODQ alone (data not
shown). A similar decrease in PFR by ODQ was observed
in kidneys stored in the presence of CORM-3 (data not
shown).
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Figure 4 | Effect of CO-RMs on urine flow rate in isolated kidneys
after cold storage. Rabbit kidneys were initially flushed with Celsior
solution alone or supplemented with (a) 50 mM CORM-A1 or (b)
CORM-3 and then subjected to a 24 h cold storage (CS) (see Materials
and Methods for details). Urine flow rate was then measured in
isolated kidneys over 90 min after a period of initial equilibration.
iCORM-A1 and iCORM-3, which do not release CO, were used as
negative controls. Each line represents the mean7s.e.m. of n¼ 6 for
each group. *Po0.05 vs CS group.
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Figure 5 | Effect of CO-RMs on glomerular filtration rate (GFR) in
isolated kidneys after cold storage. Rabbit kidneys were initially
flushed with Celsior solution alone or supplemented with (a) 50 mM
CORM-A1 or (b) CORM-3 and then subjected to a 24 h cold storage
(CS) (see Materials and Methods for details). GFR was then measured
in isolated kidneys over 90 min after a period of initial equilibration.
iCORM-A1 and iCORM-3, which do not release CO, were used as
negative controls. Each line represents the mean7s.e.m. of n¼ 6 for
each group. *Po0.05 vs CS group.
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Figure 6 | Effect of CO-RMs on respiratory control index (RCI) in
isolated renal mitochondria. Kidneys were freshly isolated (CON) or
subjected to a 24 h cold storage (CS) period in the presence or
absence of (a) CORM-A1 or (b) CORM-3 (see Materials and Methods
for details). Mitochondria were then isolated and the RCI was
assessed in the presence of malate and glutamate as substrates and
ADP. iCORM-A1 and iCORM-3, which do not release CO, were used as
negative controls. Each bar represents the mean7s.e.m. of n¼ 5–6
for each group. *Po0.05 vs control (CON); wPo0.05 vs CS group.
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CO-RMs improve tubular function at reperfusion after CS
As shown in Table 1, glucose (RGLU) and Na
þ (RNa)
reabsorption were found to be significantly increased in
kidneys that were previously flushed with CORM-A1. Both
RGLU and RNa levels were unchanged in kidneys treated with
iCORM-A1. Notably, both iCORM-3 and iCORM-3 did not
significantly affect RGLU and RNa levels (Table 1). The urinary
release of gamma-glutamyltransferase (GGT), a marker of
tubular injury, was increased at reperfusion after CS and
treatment with CORM-A1 or CORM-3 (but not iCO-RMs)
reduced these values by more than two-fold. Urinary nitrite
was significantly reduced when CORM-3 was used, but was
unchanged after treatment with CORM-A1.
DISCUSSION
CO-RMs are a novel class of bioactive agents that have been
recently identified to substantiate the important biological
function of CO in mammals.23–25 We have proposed that
their pharmacological properties could be exploited for the
therapeutic delivery of CO in the treatments of a variety of
pathophysiological states that affect the cardiovascular and
immune systems.25,27,28,31 Here, we show that CO liberated
from water-soluble CO-RMs exerts significant beneficial
effects on renal vascular function of fresh isolated kidneys
as well as kidneys stored at low temperatures (41C) in Celsior
solution, a clinical strategy commonly used to preserve
organs for transplantation. The fact that CO-RMs were
used only during the flushing procedure prior to CS indicates
the feasibility of utilizing these CO carriers as adjuvants
of preservation solutions to greatly limit the damage of
donor organs.
Impairment of renal blood flow during I–R plays a
significant role in the exacerbation of tissue injury in a
number of kidney diseases.32 It has been shown that a
persistent reduction in renal blood flow can be attributed to a
decreased GFR observed in renal allografts following an
ischemic event.33 In addition, intense vasoconstriction and
endothelial damage are prominent features of CS-mediated
injury.34 In the present study, we initially found that freshly
isolated kidneys perfused with CORM-A1, a boron-contain-
ing CO generator, resulted in a significant increase in PFR.
Moreover, PFR markedly increased in reperfused isolated
kidneys previously flushed with either CORM-A1 or
CORM-3 and subjected to a 24 h CS procedure. The fact
that iCO-RMs were ineffective clearly demonstrates that CO
is directly responsible for the observed pharmacological
effects. Since the perfusion pressure in our isolated model
was kept constant (100 mmHg), we conclude that the
increase in PFR by CO-RMs is mainly due to a decrease in
vascular resistance. We also found that the beneficial vascular
effects mediated by CORMs were lost in the presence of
ODQ, a guanylate cyclase inhibitor. These results are
supported by data showing that endogenous CO promotes
renal vasodilatation in chronically hypoxic rats35 and are
consistent with previous studies from our laboratory
demonstrating that both CORM-3 and CORM-A1 exert
vasorelaxation of precontracted aortas as well as systemic
hypotension through stimulation of the cyclic 30, 50 guano-
sine monophosphate pathway.26,27 We cannot exclude a priori
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Figure 7 | Effect of ODQ, a guanylate cyclase inhibitor, on
perfusion flow rate in freshly isolated kidneys and after cold
storage. (a) ODQ (30mM), a soluble guanylate cyclase inhibitor, was
perfused 30 min before the addition of CORM-A1 in freshly isolated
kidneys at 371C. (b) ODQ (30mM) was added to the flushing Celsior
solution (41C) in combination with CO-RMs prior to 24 h cold storage
(CS). Changes in perfusion flow rate were then measured in the
isolated perfused rabbit kidney system (see Materials and methods
for details). Each line represents the mean7s.e.m. of n¼ 5 for each
group. *Po0.05 vs control (CON) or CS alone.
Table 1 | Effect of CO-RMs on tubular function and other biochemical parameters at reperfusion after cold storage (CS)
%RGLU %RNa GGT (U/l) Nitrite (lM) % Protein leakage
CS 54.876.3 16.472.8 18.079.2 3.870.5 7.070.2
CS+CORM-A1 (50mM) 72.773.9* 29.371.9* 8.772.1 3.470.4 7.770.3
CS+iCORM-A1 (50mM) 54.377.0 18.172.8 30.0712.8 3.470.6 7.671.1
CS+CORM-3 (50mM) 69.876.9 25.372.8 6.472.7 2.270.4* 7.370.5
CS+iCORM-3 (50mM) 71.375.0 26.073.4 15.875.5 5.870.5 8.070.6
RGLU=glucose reabsorption; RNa=sodium reabsorption; GGT=gamma-glutamyltransferase.
[2]Isolated rabbit kidneys were flushed with Celsior solution (41C) alone or Celsior
supplemented with CORM-A1 or CORM-3. Kidneys were then stored at 41C for 24 h and then reperfused ex vivo as discussed in the Materials and Methods section.
*Po0.05 vs CS.
Kidney International (2006) 69, 239–247 243
A Sandouka et al.: Effect of CO-RMs on renal function o r i g i n a l a r t i c l e
that other mechanisms, particularly activation of Kþ
channels36 and modulation of the vasoconstrictor endothe-
lin,37 could participate in CO-mediated renal vasorelaxation
as these two pathways have been shown to be potential
targets for CO-RMs in cardiac and smooth muscle cells.25,38
Thus, the present study emphasizes that water-soluble
CO-RMs exert a positive effect on the vascular activity of
the kidney and confirm that CO is crucial in maintaining
renal hemodynamics after cold ischemia.
The increase in GFR and UFR mediated by CO-RMs was
accompanied by a markedly improved glucose and sodium
reabsorption as well as reduced GGT activity, suggesting that
CO also protects tubular function against the detrimental
effect of cold ischemia and reperfusion. Our data are
consistent with a previous report by Arregui and colleagues
showing that Mn2(CO)10 (CORM-1), a light-sensitive non-
water-soluble CO-RM firstly identified by our group and
found to possess biological activities,23,24 plays an important
role in the control of renal hemodynamics and function in
vivo. The authors reported that an intrarenal administration
of CORM-1 in Sprague–Dawley rats increases renal blood
flow (þ 54%), GFR (þ 38%) and urinary cyclic 30, 50
guanosine monophosphate excretion (þ 128%), and that
inhibition of HO activity progressively compromises renal
hemodynamics leading to acute renal failure, an effect that
was completely reversed by CORM-1.39 Similarly, Vera et al.40
reported that CORM-3 significantly decreased the levels of
plasma creatinine and limited renal damage in a mouse
model of ischemia-induced acute renal failure. Collectively,
these and our present results suggest that CO synthesis and
activation of guanylate cyclase are dynamically involved in
counteracting renal dysfunction in a variety of stress
conditions that affect the physiology of the kidney.
In addition to its well-established beneficial effects on
vascular activity, CO promotes anti-inflammatory16 and
antiapoptotic effects15 that can contribute to the defence
against tissue injury. The molecular mechanisms underlying
these cytoprotective actions by CO are not fully understood
at present, but emerging evidence highlights the pleiotropic
properties of this gaseous molecule. Administration of CO
gas in vivo has been shown to improve kidney graft function
in part by decreasing the levels of proinflammatory mediators
and inhibition of apoptosis.6 Recent studies from our group
confirm the anti-inflammatory action of CO by showing that
CORM-3 inhibits the increase in tumor necrosis factor alpha
and nitric oxide in endotoxin-stimulated macrophages.28
Moreover, CORM-2 appears to modulate the production of
reactive oxygen species generated by nicotinamide adenine
dinucleotide phosphate oxidase and the mitochondrial
respiratory chain in human airway smooth cells.41 This is
in line with the data presented in this study showing that the
use of CORM-3 during the CS procedure reduced urinary
nitrite levels and improved kidney mitochondrial respiration
at reperfusion. Since CO preferentially binds to metal-
centered proteins, heme-dependent cytochromes present in
the mitochondria could potentially serve as a possible target
for CO to confer protection against oxidant-mediated injury.
Indeed, mitochondria play a fundamental role in I–R injury
in organ transplantation5 by controlling apoptotic events42
and the generation of reactive oxygen species.43 In this
context, uncoupling has been suggested as an important
mechanism for reducing reactive oxygen species generation,44
and the concept that a continuous mild production of
reactive oxygen species from mitochondria is essential for
life is fully supported by experimental evidence.45 Notably, in
pig hearts subjected to cardiopulmonary bypass with
cardioplegic arrest, treatment with CO gas showed signifi-
cantly higher adenosine 50 triphosphate and phosphocreatine
levels, less interstitial edema, and reduced apoptosis of
cardiomyocytes, suggesting that CO can improve the energy
status of the cell.46
The ability of CO-RMs to confer significant protection
against renal cold ischemia and reperfusion damage is in
agreement with the beneficial effects mediated by CO gas and
HO-1-derived CO against kidney dysfunction in various
models of disease. Kidney grafts preserved in University of
Wisconsin solution at 41C for 24 h and orthotopically
transplanted into syngeneic rats previously treated with CO
gas displayed an increased renal cortical blood flow and was
accompanied by enhanced serum creatinine clearance and
improved animal survival.6 Treatment of organ donors and
long-term recipients with methylene chloride, a CO-generat-
ing chemical, ameliorated renal function and reduced
histological signs of deterioration in a rat model of kidney
allograft rejection.47 Similarly, induction of HO-1 preserved
kidney graft function and prevented postreperfusion apop-
tosis after cold ischemia, an effect that was completely
reversed by inhibition of HO activity.48 Moreover, over-
expression of HO-1 either by hemin or gene transfer results
in protection against renal CS-mediated damage and renders
transplanted kidneys more resistant to I–R injury.49,50
It is intriguing to note that in freshly isolated kidneys
perfused at 371C, CORM-A1 promoted a significant increase
in PFR, UFR, and GFR, while CORM-3 did not change renal
hemodynamics and function under this condition. This is
rather surprising since both agents were equally effective in
preventing renal dysfunction when used during the flushing
procedure at 41C prior to CS and reperfusion. The reason for
this apparent discrepancy may lie in the different chemical
features and rate of CO release from the two drugs used.
CORM-3, a ruthenium-based carbonyl complex, is known to
release CO very rapidly in physiological buffers and plasma at
371C with a half-life ranging from 1 to 5 min.24,25 In contrast,
CORM-A1 liberates CO slowly and the rate of CO release
is strictly dependent on pH and temperature.26 In fact, the
half-life of CORM-A1 in phosphate buffer at 371C is
approximately 21 min26 and is similar that one found in this
study using Krebs buffer perfusion solution. The rate of CO
release from CO-RMs in Celsior at 41C is dramatically
reduced despite being still 10 times faster for CORM-3
(14.071.0 nmol/h) than CORM-A1 (1.3970.05 nmol/h).
Given the large volume of recirculating perfusate used in
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the isolated system, which is open to atmospheric exchange,
the CO rapidly liberated from CORM-3 in the perfusate at
371C may be lost from the system before it reaches the renal
circulation at effective concentrations. This technical pro-
blem would be avoided with CORM-A1, which effectively
delivers CO to the kidney circulation by virtue of its features
as a slow releaser at 371C. However, at low temperatures
(41C), the rate of CO release from CORM-3 and CORM-A1
is significantly decreased and CO liberated more gradually
from both compounds during the 24 h CS period could exert
a stronger pharmacological activity that is manifested at
reperfusion. This indicates that the kinetics of CO release
from CO-RMs under different conditions plays a crucial role
in determining and maximizing the beneficial effects of these
CO carriers. Although both CORM-3 and CORM-A1 afford
the same degree of renoprotection when used at low
temperatures, our data show that during the first 30 min of
reperfusion both vascular activity (PFR) and renal function
(GFR and UFR) are better in kidneys previously treated with
CORM-A1, suggesting that slow CO releasers may be the
preferred choice for organ preservation.
In summary, our results emphasize that CO liberated from
CO-RMs has a protective vasodilatory effect, improves renal
function and increases mitochondrial respiration after
cold ischemia and reperfusion. These findings suggest that
CO-RMs could be used therapeutically in preservation
solutions as an efficacious strategy to prevent the injury
sustained by organs during CS prior to transplantation.
MATERIALS AND METHODS
Chemicals, reagents and solutions
CORM-3 and its inactive counterpart (iCORM-3) as well as CORM-
A1 and iCORM-A1 were synthesized and prepared as previously
reported by us.25,26 Adenosine diphosphate was from Boehringer
Mannheim (Lewes, UK) and all other reagents were obtained from
Sigma Aldrich. Celsior, a universal CS solution for preservation of
organs,51 was from Imtix-Sangstat (Lyon, France).
Surgical procedure
Male New Zealand White rabbits (2.5–4 kg) were supplied by Harlan
UK Ltd. All experiments were performed under Home Office
licenses (UK) under the Animal (Scientific Procedures) Act, 1986.
After anesthesia, the renal arteries were cannulated and kidneys were
flushed with 30 ml perfusion solution at 371C.
Isolated perfused rabbit kidney
The kidney was perfused using a closed perfusion circuit built from
nylon tubing based on a system described previously.52 Oxygenated
Krebs solution was perfused at constant pressure (100 mmHg)
through the renal artery while the renal vein was kept open to allow
the perfusate to run through the organ chamber and then recirculated
again. Sampling of perfusate for biochemical analysis and measurement
of hemodynamic parameters were undertaken at set intervals.
Experimental protocols
Isolated kidneys were divided in two major protocols. In protocol A
(n¼ 6 for each group), kidneys were not subjected to CS but were
immediately perfused on the circuit at 371C; CO-RMs (0, 10, 25,
and 50 mM) or iCO-RMs (50 mM) were added to the perfusion
solution in the last 45 min of the 2 h perfusion period to investigate
their effects on kidney function. In protocol B (n¼ 6 for each
group), kidneys were flushed with 60 ml cold Celsior solution alone
or supplemented with 50 mM CO-RMs or iCO-RMs and bathed at
41C for 24 h in Celsior prior to evaluating their hemodynamic
functions on the isolated system. In an additional set of experiment,
ODQ (30 mM), a soluble guanylate cyclase inhibitor, was perfused
30 min before the addition of CORM-A1 in freshly isolated kidneys
at 371C or added to the flushing Celsior solution (41C) in
combination with CO-RMs prior to CS.
Functional and biochemical parameters
PFRs and UFRs were measured every 15 min after 30 min of initial
stabilization and expressed as ml/min/g tissue. Perfusate and urine
samples from renal vein and ureter were collected at the same time
points for biochemical study. The samples were kept at 801C until
further analysis. GFR was calculated by measuring urine and
perfusate creatinine levels according to the following formula:
GFR¼UFRurine creatinine/perfusate creatinine. Glucose, Naþ ,
creatinine, and GGT levels were measured using a biochemical
analyzer. Nitrite levels were determined in the urine using the Griess
method as described previously.53 Protein leakage was assessed by
measuring the protein concentration (Lowry method) appearing in
the urine.
Detection of CO release
The release of CO from CO-RMs in Krebs buffer perfusion (371C)
and in Celsior (41C) solutions was assessed spectrophotometrically
by measuring the conversion of deoxymyoglobin to MbCO using a
method previously described by us.23,26 Since both CORM-3 and
CORM-A1 liberate 1 mol of CO/mol of compound and because we
used 1 ml of solution containing myoglobin, the maximum amount
of CO that can be released from 50 mM CO-RMs into the solution is
50 nmol. Therefore, the rate of CO release was expressed as nmol/h.
Isolation of rabbit kidney mitochondria
At the end of the reperfusion studies on the isolated system, cortical
mitochondria from each kidney were isolated by homogenization
and differential centrifugation as reported before.54
Measurement of oxygen consumption in isolated
mitochondria
All experiments were carried out using a 2 ml capacity incubation
chamber maintained at 301C and a Clark electrode attached to an
oxygen monitoring system (Yellow Springs Instruments, Yellow
Springs, OH). Incubation was carried out using approximately 1 mg
protein of isolated mitochondria resuspended in 1 ml respiratory
buffer supplemented with 0.5 mg bovine serum albumin. Mito-
chondrial respiration was measured using malate (5 mM)þ gluta-
mate (5 mM) as substrates. State 3 respiration was initiated by the
addition of adenosine diphosphate and state 4 respiration was
measured after all the ADP was converted to adenosine 50
triphosphate. The RCI, which indicates the tightness of the coupling
between respiration and phosphorylation, was calculated as the ratio
between states 3 and 4.
Statistical analysis
Statistical analysis was performed using one-way analysis of variance
combined with the Bonferroni test for multiple comparisons. When
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differences were established between groups, an unpaired two-tailed
t-test was used to assess the statistical significance between two
groups at each time point. Data were presented as mean7s.e.m. and
differences were considered to be statistically significant at Po0.05.
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